至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer

J Hematol Oncol. 2021-04; 
Shi Chen, Can Yang, Zu-Wei Wang, Jian-Fei Hu, Jing-Jing Pan, Cheng-Yu Liao, Jia-Qiang Zhang, Jiang-Zhi Chen, Yi Huang, Long Huang, Qian Zhan, Yi-Feng Tian, Bai-Yong Shen, Yao-Dong Wang
Products/Services Used Details Operation
Custom Vector Construction The anti-phosphorylation –SRSFs was constructed in GenScript Inc (Nanjing, China) Get A Quote

摘要

background: Both aberrant alternative splicing and m6A methylation play complicated roles in the development of pancreatic cancer (PC), while the relationship between these two RNA modifications remains unclear. methods: RNA sequencing (RNA-seq) was performed using 15 pairs of pancreatic ductal adenocarcinoma (PDAC) tissues and corresponding normal tissues, and Cdc2-like kinases 1 (CLK1) was identified as a significantly upregulated alternative splicing related gene. Real-time quantitative PCR (qPCR) and western blotting were applied to determine the CLK1 levels. The prognostic value of CLK1 was elucidated by Immunohistochemistry (IHC) analyses in two independent PDAC cohorts. The functional characterizations a... More

关键词

Alternative splicing, CLK1, Cyclin L2, M6A Modification, METTL14, Pancreatic cancer, SRSF5